ArticleGenetics, selection, evolution : GSE2020
The economic value of R
Article in Genetics, selection, evolution : GSE, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic selection for white spot syndrome virus resistance in whiteleg shrimp boosts survival under an experimental challenge test.Scientific reports · 2020Article
- Why breed disease-resilient livestock, and how?Genetics, selection, evolution : GSE · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroparasitic diseases are caused by bacteria and viruses. Genetic improvement of resistance to microparasitic diseases in breeding programs is desirable and should aim at reducing the basic reproduction ratio [Formula: see text]. Recently, we developed a method to derive the economic value of [Formula: see text] for macroparasitic diseases. In epidemiological models for microparasitic diseases, an animal's disease status is treated as infected or not infected, resulting in a definition of [Formula: see text] that differs from that for macroparasitic diseases. Here, we extend the method for the derivation of the economic value of [Formula: see text] to microparasitic diseases.
methodsWhen [Formula: see text], the economic value of [Formula: see text] is zero because the disease is very rare. When [Formula: see text]. is higher than 1, genetic improvement of [Formula: see text] can reduce expenditures on vaccination if vaccination induces herd immunity, or it can reduce production losses due to disease. When vaccination is used to achieve herd immunity, expenditures are proportional to the critical vaccination coverage, which decreases with [Formula: see text]. The effect of [Formula: see text] on losses is considered separately for epidemic and endemic disease. Losses for epidemic diseases are proportional to the probability and size of major epidemics. Losses for endemic diseases are proportional to the infected fraction of the population at the endemic equilibrium.
resultsWhen genetic improvement reduces expenditures on vaccination, expenditures decrease with [Formula: see text] at an increasing rate. When genetic improvement reduces losses in epidemic or endemic diseases, losses decrease with [Formula: see text] at an increasing rate. Hence, in all cases, the economic value of [Formula: see text] increases as [Formula: see text] decreases towards 1. DISCUSSION: [Formula: see text] and its economic value are more informative for potential benefits of genetic improvement than heritability estimates for survival after a disease challenge. In livestock, the potential for genetic improvement is small for epidemic microparasitic diseases, where disease control measures limit possibilities for phenotyping. This is not an issue in aquaculture, where controlled challenge tests are performed in dedicated facilities. If genetic evaluations include infectivity, genetic gain in [Formula: see text] can be accelerated but this would require different testing designs.
conclusionsWhen [Formula: see text], its economic value is zero. The economic value of [Formula: see text] is highest at low values of [Formula: see text] and approaches zero at high values of [Formula: see text].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.